Physician profile
Sam Kidane
NPI 1497412399
$2,954.36
in general payments reported to CMS, 2019-2025
30 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,095 · 2023: $974 · 2024: $735 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.76 | 2022-2025 | |
| Glaxosmithkline, LLC. | $404.45 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $264.97 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $255.22 | 2022-2024 | |
| Novo Nordisk INC | $251.70 | 2022-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $169.85 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $162.08 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $157.46 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $79.89 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $73.90 | 2023-2024 | Rexulti |
| Amgen INC. | $61.69 | 2023-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.70 | 2022-2024 | Jardiance |
| Tactile Systems Technology INC | $59.44 | 2024 | Flexitouch Plus, Entre Plus |
| Astellas Pharma US INC | $58.13 | 2022-2023 | Veozah |
| Biocryst US Sales Co., LLC | $53.02 | 2022-2023 | Orladeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $46.44 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $46.29 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $45.05 | 2022-2025 | Gardasil 9, Capvaxive |
| Gilead Sciences, INC. | $36.09 | 2023-2025 | |
| Exact Sciences Corporation | $34.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $34.15 | 2023-2024 | |
| Corium, LLC | $32.92 | 2022-2024 | Azstarys |
| Mylan Specialty L.P. | $30.89 | 2023 | Yupelri |
| Covis Pharma Gmbh | $24.38 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.75 | 2022 | |
| Avanos Medical | $21.56 | 2022 | |
| Fidia Pharma USA INC. | $18.83 | 2023 | Triluron, Hymovis |
| Indivior INC. | $18.75 | 2024 | Sublocade |
| Braeburn INC. | $13.58 | 2023 | Brixadi |
| Supernus Pharmaceuticals, INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Kidane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.